Merck Vioxx Formulary Status Retained Since VIGOR GI, CV Label Change
Executive Summary
Vioxx has retained key formulary positions and added new accounts since the VIGOR label change, Merck Human Health President-Europe Per Wold-Olsen said during the company's annual business briefing in Whitehouse Station, N.J., Dec. 10
You may also be interested in...
Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger
Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor
Merck Arcoxia 6,000-Patient Trial Will Study GI, Cardiac Events
Merck will conduct a 6,000-patient study of Arcoxia focusing on patient discontinuations due to gastrointestinal adverse events
Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety
The updated labeling for Pharmacia/Pfizer's COX-2 inhibitor Celebrex draws an unequivocal distinction between it and Merck's COX-2 Vioxx